OH BOY!!! BETTER WATCH OUT ON THIS ONE. CYPRO AND ZANAFLEX TOGETHER, WOW !! ALSO ANTIARYYTHMIC MEDS.
YA' LL, , , , ALL TAKE NOTE > [Original Message] > From: CDER MEDWATCH LISTSERV <[EMAIL PROTECTED]> > To: <[EMAIL PROTECTED]> > Date: 4/11/2007 3:03:56 PM > Subject: FDA - MedWatch - Zanaflex (tizanidine hydrochloride) Tablets and Capsules - Changes to the CONTRAINDICATIONS and WARNINGS Sections of the Approved Product Labeling > > MedWatch - The FDA Safety Information and Adverse Event Reporting Program > > Acorda Therapeutics and FDA informed healthcare professionals of changes > to the CONTRAINDICATIONS and WARNINGS Sections of the product labeling > for Zanaflex, a drug used to treat spasticity, In pharmacokinetic > studies where tizanidine was coadministered with either fluvoxamine or > ciprofloxacin (CYP1A2 inhibitors), the serum concentration of tizanidine > was significantly increased and potentiated its hypotensive and sedative > effects. Although there are no clinical studies evaluating the effects > of other CYP1A2 inhibitors on tizanidine, coadministration of tizanidine > with other CYP1A2 inhibitors (zileuton, other fluroquinolones, > antiarrythmics, cimetidine, famotidine, oral contraceptives, acyclovir > and ticlopidine) should be avoided. > > Read the complete MedWatch 2007 Safety summary, including a link to the > manufacturer's Dear Healthcare Provider Letter regarding this issue at: > http://www.fda.gov/medwatch/safety/2007/safety07.htm#Zanaflex > > _________________________________________________________________ > > To ensure delivery of these timely alerts to your in-box and prevent rejection of the notice by a spam filter, please add our MedWatch address, [EMAIL PROTECTED], to your address book. > > Thank you for using FDA MedWatch as a trusted source for timely safety information on drugs, devices and diagnostics regulated by the U.S. Food and Drug Administration. If you find this e-mail notification helpful, please consider telling colleagues and friends about MedWatch and this e-mail notification process. They can learn more and subscribe to the e-list at http://www.fda.gov/medwatch. > > To send a comment or question to the MedWatch program: http://www.fda.gov/medwatch/feedback.htm > > To unsubscribe from this listserve: > https://list.nih.gov/cgi-bin/wa?SUBED1=medwatch&A=1
